AbCellera Biologics Inc.
AbCellera Biologics Inc. (ABCL) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ABCL · as of Mar 31, 2025
Ownership Breakdown
136
Institutional Holders
▼ 14 vs Q4
$282.87M
Total Inst. Value
▼ $51.05M vs Q4
305.38M
Shares Outstanding
freeFloat 67.24%
125.41M
13F Shares Held
▲ 11.50M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ABCL largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BAKER BROS. ADVISORS LP pharmaceutical preparations | 27.53M | 9.25% | 9.25% | $61.38B | May 15, 2025 | — held |
UBS ASSET MANAGEMENT AMERICAS INC pharmaceutical preparations | 15.67M | 5.26% | 5.26% | $34.95B | May 19, 2025 | ▲ 11.17M |
CAPITAL WORLD INVESTORS pharmaceutical preparations | 13.36M | 4.49% | 4.49% | $29.80B | May 12, 2025 | ▲ 5.43M |
BAILLIE GIFFORD & CO pharmaceutical preparations | 11.20M | 3.76% | 3.76% | $24.97B | May 7, 2025 | ▼ 1.04M |
VOYA INVESTMENT MANAGEMENT LLC pharmaceutical preparations | 10.62M | 3.57% | 3.57% | $23.69B | Jun 18, 2025 | — held |
UBS GROUP AG pharmaceutical preparations | 5.08M | 1.71% | 1.71% | $11.33B | May 13, 2025 | ▲ 3.11M |
ORBIMED ADVISORS LLC pharmaceutical preparations | 4.18M | 1.40% | 1.40% | $9.32B | May 15, 2025 | — held |
ARROWMARK COLORADO HOLDINGS LLC pharmaceutical preparations | 4.11M | 1.38% | 1.38% | $9.15B | May 15, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 3.58M | 1.20% | 1.20% | $7.97B | May 2, 2025 | ▼ 520.4K |
TWO SIGMA INVESTMENTS, LP pharmaceutical preparations | 3.13M | 1.05% | 1.05% | $6.97B | May 15, 2025 | ▼ 130.5K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
19
Increased
+22.56M shares0
New Positions
first time holders20
Decreased
−8.51M shares0
Sold Out
fully exitedNet shares change (top 50)
+14.05M
+22.56M / −8.51M
Net new holders
-1
0 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ABCL insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Montalbano John S. director | May 14, 2026 | Purchase | 20,000 | $4.77 | $95.4K | 241.0K | Form 4 ↗ |
Thermopylae Holdings Ltd. 10 percent owner | Feb 27, 2026 | Purchase | 38,000 | $3.44 | $130.7K | 56.13M | Form 4 ↗ |
Thermopylae Holdings Ltd. 10 percent owner | Feb 26, 2026 | Purchase | 177,457 | $3.27 | $580.3K | 56.10M | Form 4 ↗ |
Booth Andrew Chief Financial Officer | Feb 27, 2026 | Purchase | 42,600 | $3.42 | $145.7K | 195.6K | Form 4 ↗ |
Booth Andrew Chief Financial Officer | Jan 1, 2026 | Award | 808,898 | $3.42 | $2.77M | 8.75M | Form 4 ↗ |
Hansen Carl L. G. Chief Executive Officer | Jan 1, 2026 | Award | 2,106,505 | $3.42 | $7.20M | 13.10M | Form 4 ↗ |
Stimart Tryn Chief Legal Officer | Jan 1, 2026 | Award | 539,265 | $3.42 | $1.84M | 4.65M | Form 4 ↗ |
Lecault Veronique Chief Technology Officer | Jan 1, 2026 | Award | 539,265 | $3.42 | $1.84M | 5.20M | Form 4 ↗ |
Quake Stephen director | Dec 1, 2025 | Award | 194,932 | $3.47 | $676.4K | 194.9K | Form 4 ↗ |
Thermopylae Holdings Ltd. 10 percent owner | Dec 18, 2025 | Gift | 225,000 | — | — | 55.92M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
AbCellera Biologics Inc. (ABCL) is primarily owned by institutional investors, who hold approximately 41.1% of total shares outstanding. Company insiders own approximately 32.76%, while retail and public investors account for the remaining 26.17%.
The largest institutional shareholder of AbCellera Biologics Inc. is BAKER BROS. ADVISORS LP, holding approximately 27.53 million shares — equal to 9.25% of outstanding shares — as of March 31, 2025.
A total of 136 institutional investors currently hold ABCL stock, with a combined institutional value of approximately $282,865,441 as of the most recent 13F filing period.
Frequently asked questions
ABCL ownershipAbCellera Biologics Inc. (ABCL) is primarily owned by institutional investors, who hold approximately 41.1% of shares. The largest shareholder is BAKER BROS. ADVISORS LP with a 9.25% stake. Company insiders hold 32.76%. Data sourced from SEC Form 13F as of March 31, 2025.